Colorectal cancer (CRC) arising in Lynch syndrome (LS) comprises tumours with constitutional mutations in DNA mismatch repair genes. There is still a lack of whole-genome and transcriptome studies of LS-CRC to address questions about similarities and differences in mutation and gene expression characteristics between LS-CRC and sporadic CRC, about the molecular heterogeneity of LS-CRC, and about specific mechanisms of LS-CRC genesis linked to dysfunctional mismatch repair in LS colonic mucosa and the possible role of immune editing. Here, we provide a first molecular characterization of LS tumours and of matched tumour-distant reference colonic mucosa based on whole-genome DNA-sequencing and RNA-sequencing analyses. Our data support two subgroups of LS-CRCs, G1 and G2, whereby G1 tumours show a higher number of somatic mutations, a higher amount of microsatellite slippage, and a different mutation spectrum. The gene expression phenotypes support this difference. Reference mucosa of G1 shows a strong immune response associated with the expression of HLA and immune checkpoint genes and the invasion of CD4+ T cells. Such an immune response is not observed in LS tumours, G2 reference and normal (non-Lynch) mucosa, and sporadic CRC. We hypothesize that G1 tumours are edited for escape from a highly immunogenic microenvironment via loss of HLA presentation and T-cell exhaustion. In contrast, G2 tumours seem to develop in a less immunogenic microenvironment where tumour-promoting inflammation parallels tumourigenesis. Larger studies on non-neoplastic mucosa tissue of mutation carriers are required to better understand the early phases of emerging tumours.
Introduction
Lynch syndrome (LS) is one of the most frequently inherited cancer predisposition syndromes, contributing to about 3% of all colorectal cancer (CRC) cases [1] . LS is defined by an autosomal dominant heterozygous constitutional mutation in one of four key mismatch repair (MMR) genes, i.e. MLH1 (∼60%), MSH2 (∼30%), MSH6, or PMS2 [2, 3] . LS-CRCs develop after the acquisition of a second somatic hit in the respective gene, leading to microsatellite (MS) instability. In contrast, MS instability in sporadic CRC (sCRC) most frequently results from promoter hypermethylation of MLH1 [4, 5] . Clinical studies have demonstrated better overall survival of LS-CRC patients than of sCRC patients [6] , which is possibly linked to local inflammation [7] in response to the production of highly immunogenic frameshift peptides transcribed from MS-instable (MSI) genes in LS mucosa [8] . Moreover, different modes of immune response have been reported to edit tumour cells associated with different LS phenotypes [9, 10] . Whole-genome and transcriptome studies published in recent years have provided deep insights into the molecular aetiology of sCRC and revealed distinct molecular subtypes with diagnostic impacts [4, [11] [12] [13] . Despite recent discoveries about the molecular genetics of LS [14] , such efforts are still missing for LS-CRC. We here present the first study of LS-CRC based on whole-genome DNA and RNA sequencing of tumour and matched tumour-distant reference samples of colonic mucosa in LS. Data for sCRC and matched healthy colonic mucosa were taken from the TCGA consortium [4] for comparison. In this study, we investigated similarities and differences in mutation and gene expression characteristics between LS-CRC and sCRC, the molecular heterogeneity of LS-CRC, possible mechanisms of tumour genesis and progression in LS linked to dysfunctional MMR in non-neoplastic colonic mucosa, and the possible role of immune editing.
Materials and methods

Sample collection from LS-CRC patients and pathological diagnoses
Paired patient-matched specimens of tumour (adenoma and/or cancer) and tumour-distant non-neoplastic mucosa as reference samples were collected from LS-CRC patients (10 with confirmed constitutional MMR mutations, and one with clinicopathological characteristics) who were identified through the German HNPCC Consortium [15, 16] (supplementary material, Table S1 ). The study was approved by the ethics committees of the Universities of Duesseldorf, Bochum, and Bonn. Samples were used for pathological examination, whole-genome DNA-sequencing and RNA-sequencing analyses, and immunohistochemical staining of CD4 (mouse anti-human, 1:100, Clone 4B12; Thermo Scientific, Darmstadt, Germany; see [17] ). For comparison, we included sequencing data of MS-stable (MSS) and MSI sCRC cases, and of healthy colonic mucosa taken from the TCGA repository (supplementary material, Table S2 ).
DNA and RNA whole-genome sequencing and primary data processing Genomic DNA was extracted from fresh frozen tissue samples after histological re-evaluation of representative sections as described elsewhere [18] . Libraries were prepared in duplicate according to the manufacturer's protocol. Whole-genome sequencing was performed by the use of Illumina's TrueSeq Sample Preparation Kit followed by paired-end sequencing on the HiSeq 2500 platform (Illumina, San Diego, CA, USA). Total RNA was purified with the RNA MicroPrep Kit (Zymo Research, Irvine, CA, USA). Complementary DNA was generated with SuperScript II Reverse Transcriptase (Invitrogen, Waltham, MA, USA). Sequencing and library preparation were performed with the same techniques as described above for genomic DNA. The quality of libraries was checked with the FastQC tool [19] . Paired-end read sequencing data were mapped to the human genome (hg19) by use of the 'segemehl' algorithm with default settings and the split read mapping option [20] . Non-mapped RNA-sequencing reads were remapped by use of the lack script in 'segemehl'. Mapped BAM files were realigned by use of the Genome Analysis Toolkit (GATK) suite [21] . Most BAM file manipulations were performed using either with house scripts or with 'samtools' [22] . The data are available in the dbGaP database (www.ncbi.nlm.nih .gov/gap) under accession number phs001407.
Mutation and MS analysis
DNA-sequencing data were used for mutation calling, mutation spectra analysis and MS slippage profiling. We applied the GATK to call single-nucleotide variants (SNVs) and InDels. Somatic mutations were defined as the set of mutations present in tumour samples but not in matched reference tissue. Somatic InDels for frameshift analyses were accepted from the GATK InDel calls of tumour alignments when no hit was found within a window (±10 bp) around the corresponding position in the reference sample. Mutation spectra were generated by calculating the ratios for every mutation type, including the information on adjacent 3 ′ /5 ′ bases, as described in Alexandrov et al. [23] . For MS slippage analysis, we selected loci of A/T monorepeats with a length of 20 bp in the reference genome. Then, the actual lengths of these repeats in the LS genomes were determined (see supplementary material, Supplementary materials and methods) and analysed in terms of their mean MS length averaged over all repeats per sample, and their frequency distribution. These so-called 'slippage profiles' were calculated by the use of repeats at loci that were detected in both the tumour and reference samples. MS-specificity analysis was performed for all MSs Table S3 ).
Gene expression analysis
Mapped RNA-sequencing gene expression data were clustered by the use of self-organizing map (SOM) machine learning, as described previously [24] . The SOM method 'portraits' the expression state of each sample in terms of a two-dimensional 40 × 40 grid image for which size and topology were chosen to allow robust identification of clusters of coexpressed genes [24, 25] . Sample diversity was visualized with a second-level SOM, which maps samples instead of genes [24] . For functional interpretation of the gene clusters, we applied gene set analysis [26] in terms of gene set enrichment Z-score (GSZ) profiles and population maps of the set genes. Gene sets were taken from the Gene Set Enrichment Analysis repository and from the literature for different functional categories defined by gene ontology, 'hallmarks of cancer', and other sources [25, 27, 28, 29] . The activity of selected pathways was estimated with the pathway signal flow method [30] . All methods were implemented in the R package 'oposSOM' used for analysis [31] .
Results
Mutation and MS characteristics
Genome-wide DNA sequencing and RNA sequencing were performed on tumour and corresponding reference tissue from 11 LS patients (supplementary material, Table S1 ). Patient samples showed large heterogeneity according to their genomic characteristics ( Figure 1 ). We stratified them into two groups, G1 and G2, for further analysis. G1 showed higher mutation numbers, a higher fraction of recurrent frameshift mutations ( Figure 1A ; supplementary material, Table S4 ) and higher MS slippage ( Figure 1B, C) than G2, and a slightly different mutation spectrum (Figure 1D , E; supplementary material, Figure S1 ). Higher MS slippage is demonstrated by the frequency distribution of the length of 20meric repeats and the related mean MS length. Out of all instable MSs, 77 were selected that separated both groups with high selectivity (supplementary material, Supplementary materials and methods and Figure S2 ). The number of somatic mutations in cancer and the mean length of the selected monorepeats anti-correlated in G1. POLE was mutated in some G1 samples ( Figure 1A ). The combination of LS constitutional mutations with somatic mutations of POLE seems to induce an additional mutation load because of POLE dysfunction, in accordance with Briggs and Tomlinson [32] . The mutation spectra resembled those previously attributed to the inactivation of MMR and impaired POLE function in CRC, respectively (spectra 6 and 10 in Alexandrov et al. [23] ). The mutation characteristics of LS-CRC were compared with those of sCRC samples available from TCGA. The mutation spectra and MS length distributions of G1 LS-CRC had similarities with those of MSI sCRC, whereas G2 LS-CRC had similarities with MSS sCRC (supplementary material, Figure S3 ). The MS length distributions in LS reference mucosa showed nucleotide loss, in contrast to normal mucosa in the TCGA samples. In summary, mutation numbers, slippage profiles and mutation spectra support two groups of LS-CRC cases.
Recurrent mutations in LS-CRC
We identified 20 genes mutated in four of five G1 LS-CRC cases but not or only once in G2 LS-CRC cases ( Figure 1A ; supplementary material, Table S5 and Figure S4A ). Among these genes were ACVR2A, TGFBR2, CDC27, AIM2, and PDS5B, which have been found to be also frequently mutated in MSI sCRC [4, 12, 33, 34] . Other genes are known to be frequently mutated in MSS sCRC (TP53 and KRAS) [4] . BRAF mutations, except for one G1 adenoma, were absent, in agreement with Oliveira et al. [35] , Nagasaka et al. [36] , and Boland and Goel [37] . Most of the genes recurrently affected by frameshifts in LS-CRC contain MSs [37] , suggesting that frameshifts are directly caused by MS instability. This also applies to existing MS instabilities in the reference tissue, evident as the base pair loss documented in Figure 1B . In summary, most of the genes recurrently mutated in G1 are also frequently mutated in sCRC.
Heterogeneity of LS-CRC gene expression phenotypes
RNA-sequencing data of LS-CRC samples were analysed by the use of SOM portrayal [24, 38] . Mean expression portraits of each G1 and G2 tissue type and difference portraits between cancer and reference from these revealed one unique cluster of genes that were upregulated in both G1 and G2 tumours ( Figure 2A ; and supplementary material, Figure S5 for single sample portraits), and that was enriched in genes that are related to proliferation and that are frequently activated in sCRC. In contrast, genes related to inflammatory processes had a high expression level specifically in G1 reference tissue only. The difference portrait between G1 and G2 indicates higher activity of proliferation, oxidative phosphorylation (Oxphos), and energy metabolism in G1.
The Euclidean distance between the expression portraits of tumours and reference tissues was calculated as a measure of diverging transcriptional programmes. In G1 tumours, it increased proportionally to the number of somatic mutations for most samples, indicating that the accumulation of mutations in G1 tumours shifts the expression patterns ( Figure 2B ). Sample diversity maps revealed that all G1 cancer samples showed high similarity and accumulated in a narrow region of the map, whereas the G1 reference samples were more diverse, The LS-CRC cases cluster into two groups, G1 and G2, differing in the number of somatic mutations, the type of mutation (more frameshift in G1), the type of constitutional mutation carrier (83% MLH1 in G1 and 40% in G2), and the recurrently mutated genes (see also supplementary material, Figure S4a ). (B) MS slippage profiles: 20-bp monorepeats in the reference genome shorten on average, and show a bimodal length distribution with different peak positions in G1 and G2 LS-CRC and reference tissue. (C) Mean MS length (MSL) as a function of mutational load: MSL and the mutational load separate G1 and G2. (D) Mean mutation spectra. The sequence context of the SNV is characterized by mutation spectra [23] that are different in G1 and G2, as revealed by their difference spectra. (E) Principal component analysis of mutation spectra.
expressing either a mucosa or an inflammatory signature ( Figure 2C ; supplementary material, Figure S6 ). Hence, the heterogeneity of active transcriptional programmes decreased during tumour formation, especially in G1. The diversity of G2 tumours was comparable with that of the G2 reference tissues, manifesting either a stromal or a mucosa signature. They showed less pronounced cancer characteristics than G1. In summary, the diversity of gene expression phenotypes supports differentiation between G1 and G2. [42] , Kosinski et al. [43] , and Whitfield et al. [45] . (B) The expression heatmap of mutated genes shows that mutations reduce the expression level in most cases. (C) The SOM summary map provides an overview of all relevant spot clusters of coexpressed genes (red) observed in the SOM portraits (compare with Figure 2A ). Spots are labelled A-F. Different regions of the map can be assigned to spots upregulated in the different tissue types as indicated. Each spot was functionally annotated by gene set analysis (see also supplementary material, Table  S6 and Figure S8 ). Four major expression modules ('stroma', 'inflammation', 'mucosa', and 'proliferation') were extracted. using GSZ metrics [25] ( Figure 3A) . Sets related to cell cycle activity, MYC target activation and CRC markers were highly expressed in cancer samples, whereas sets related to immune response, mucosa and stroma functions were overexpressed in reference samples of G1 and G2. The expression heatmap of genes with recurrent somatic mutations and with constitutional mutations in G1 revealed that many of these genes showed reduced mRNA expression in the mutated state ( Figure 3B ), in agreement with previous results obtained in MSI sCRC [12] and with their frequent functions as tumour suppressors (supplementary material, Table S5 ).
Next, we determined clusters of coexpressed genes in the expression landscape ( Figure 3C ). Six major clusters labelled A-F were identified and functionally assigned by the use of gene set analysis, namely: (A) immune response, (B) stroma, (C) mesenchyme, (D) proliferation, (E) Oxphos, and (F) healthy mucosa (see also supplementary material, Table S6, Figure S7 and Figure S8 ). We found correspondence of the expression 248 H Binder et al signatures of LS-CRC with those previously detected in studies on sCRC, and healthy and inflamed colon [39] [40] [41] [42] [43] [44] . The functional characteristics of four consensus molecular subtypes of sCRC extracted recently [11] correspond to the functional context of our four main modules, whereby our 'proliferation' signature agrees with the signature of 'canonical CRC' (supplementary material, Figure S9 ). It is characterized by increased expression of WNT targets, among them CD44, Birc5, CCND1, MYC, and ASCL2, all located in the proliferation spot D, and it resembles the signature of the proliferative compartment in the lower crypt of healthy colon [43] (supplementary material, Figure S9C ). Comparison with the TCGA sCRC samples shows that reference mucosa of LS mutation carriers is more heterogeneous than normal (non-LS) mucosa, which is exclusively characterized by the mucosa expression signature (supplementary material, Figure S10 ).
Pathway activity analysis suggested that mutations of ACVRA, TCF7L2 and TGFBR2 in G1 LS-CRC affect 'MYC activity' (supplementary material, Figure S11 ). In summary, gene expression in the LS samples can be characterized by four main modules, whereby the 'proliferative' module is similar to the 'canonical CRC' signature, the 'mucosa' module is also characteristic of 'healthy, non-LS mucosa' in TCGA, and the 'inflammation' and 'stroma' modules are specific for reference mucosa of G1 and G2, respectively.
Pre-oncogenic immune response in G1 mucosa
In reference mucosa of G1, the activity of expression signatures related to immune response exceeded that in G1 cancer (P < 0.02, paired-sample Wilcoxon test), that in all tissue types of G2 ( Figure 4A ), and that in sCRC and normal 'non-LS' mucosa (supplementary material, Figure S10B ). It was characterized by overexpression of CD3, CD4, and CD19 [local false discovery rate of <0.01], and, to a lesser extent, of CD8, suggesting infiltration of T-immune and B-immune cells as observed by others for MSI sCRC [44, 45, 46] . This finding is supported by analysis of B-cell and T-cell receptor pathways, which revealed high activity of the NFkappaB, MAPK and PIK3 branches in G1 reference mucosa (supplementary material, Figures S12 and S13). Moreover, chemokine expression data indicated coexpression of special receptor-ligand pairs in the 'inflammation' expression signature ( Figure 4B ), and high activity of the branch B-cell adsorption in the 'leukocyte transendothelial migration pathway' in G1 LS reference tissue (supplementary material, Figure S14 ). The inflammation signature (spot A) was co-regulated with a gene set subsumed as 'coordinated immune response cluster' in sCRC [44] (supplementary material, Figure S9E ) and with immune-checkpoint genes (ICGs) encoding T-cell inhibitors [47, 48] (Figure 4C ; supplementary material, Figure S9E ). Another subset of chemokines antagonistically switched as compared with the 'anti-tumoural' inflammatory signature and were upregulated in LS-CRC ( Figure 4B , spot D). This 'pro-tumoural' immune response included the chemokines CXCL1-3, CXCL1-8 (IL-8), and CXCL1-10, which are also upregulated in sCRC [49, 50] .
Genes associated with the presentation of class II HLAs antigens accumulated in spot A together with their regulators CIITA and RFX5 ( Figure 4C ). CD4+ T cells respond to class II HLAs that are expressed by various tumours of non-lymphoid origin, including a subset of sCRCs [51] . Hence, CD4 expression in reference tissue of G1 suggests infiltration by CD4+ T cells that recognize class II HLAs. Indeed, CD4+ staining of microscopic slides of the samples studied ( Figure 4E , F) confirmed that CD4+ cells accumulated throughout the stroma of G1 reference tissue preferentially close to the epithelium, in contrast to the most de-differentiated parts of the G1 and G2 tumours and G2 reference mucosa, which were almost completely devoid of T cells and showed rather moderate CD4+ staining.
Both the number of neo-antigens predicted in G1 LS-CRC from the DNA-sequencing data and the mean expression of all HLA class II genes in G1 reference tissue increased as a function of the mutational load in LS-CRC ( Figure 4D ). The immune response in reference tissue of G1 might be induced by cell damage and the expression of immunogenic frameshift peptide antigens [52] . We interpret the mutational load in LS-CRC as a proxy for the mutational activity in LS reference mucosa. This assumption is supported by the fact that >50% of the MSs selected as MSI in G1 cancer were already instable in G1 reference mucosa (supplementary material, Figure S2A ). Also, B2M, a regulator of HLA class I genes, was co-regulated with the immune response cluster in spot A together with HLA class I genes (supplementary material, Figure  S15 ), suggesting that there was also presentation of these antigens in reference mucosa. Strong downregulation of the specific 'inflammation' signature (spot A) in cancers and adenoma of G1 suggests immune escape [46] . In summary, reference mucosa of G1 patients, in contrast to that of G2 patients, shows a strong immune response that appears to suppress cancer development until the cells undergo immune escape.
Discussion
We found remarkable heterogeneity of LS regarding: (1) the mutation frequency and MS instability in LS tumours, (2) the inflammatory state of pre-oncogenic mucosa, and (3) the mechanism of tumourigenesis via immune editing. We found it suggestive to stratify the LS cases into two groups whereby, overall, G1 LS-CRC shows strong similarities with the mutation characteristics of (MLH1-silenced) MSI sCRC, whereas G2 LS-CRC shows weaker MS instabilities and fewer mutations. the constitutional mutation and the mutational characteristics. Regarding its molecular mechanism, impaired MLH1 impedes proper localization of repair proteins near the mismatch and reduces the efficiency of MMR [53] , with consequences for the resulting mutational load. Additional somatic mutations of POLE and MSH3, both of which are observed in G1 LS-CRC and are involved in MMR, are expected to further increase the numbers of somatic mutations that accumulate during tumour progression. These mechanisms could explain the higher mutation numbers and MS slippage observed in G1 LS-CRC. Interestingly, MLH1-deficient haplotypes are associated with the presence and family history of colonic inflammatory diseases, suggesting enhanced susceptibility of MLH1 mutation carriers to inflammation [54, 55] .
H Binder et al
The reason for the increased contribution of C > G substitutions observed in the mutation spectra of G1 cancers is unclear. One possible factor is increased activity of cytidine deaminases of the APOBEC family, which is also found in many cancers with local hypermutation patterns [23] (supplementary material, Figure S9D ). The different C > T transition frequencies between G1 and G2 cancers possibly reflect differences in DNA methylation between the two groups [56] . Hereditary cancers can mimic the DNA hypermethylation patterns observed in sporadic cancers [36, 57] . Genes that are hypermethylated in sCRC show differential expression between G1 and G2, in support of this hypothesis (supplementary material, Figure S9F ).
Inflammation in G1 mucosa enforces immune escape
We found strong immune responses in G1 reference mucosa that were not evident in G2. Inflammatory responses play an important role in the progression of a variety of solid tumours, and particularly of CRC, owing to the cumulative effect of sequential genetic alterations, leading to the expression of tumour-associated antigens [58] . Thus, inflammation can act in two ways, either promoting or suppressing tumourigenesis [59] . This is also evident in LS, where, in G1 reference mucosa, 'antitumour' inflammation can be assumed to suppress tumourigenesis, whereas 'pro-tumour' inflammation in both G1 and G2 LS-CRC promotes it ( Figure 4B ). Notably, a specific immune response was detected in LS mutation carriers by means of peripheral blood analysis [60] and via the detection of premalignant MMR-deficient crypt foci [52] , suggesting that an immunological interaction between emerging MMR lesions and the immune system occurs early during the course of LS. Interestingly, CTNNB1 was mutated in three of five G1 cancers (60%) but not at all in adenoma (G1 and G2) and G2 cancer cases ( Figure 1A ) and relatively rarely in the TCGA sCRC cases studied (17% in MSI cases and 8% in MSS cases). CTNNB1 mutations were suggested to be associated with a subgroup of LS CRCs emerging from MMR-deficient crypt foci that give rise to non-polypous cancer precursors [61] . The question of whether MMR inactivation in the analysed tumours was an event secondary to polypous growth (e.g. caused by APC mutation) or the initial event, as suggested by the CTNNB1-mutant tumours described in Ahadova et al. [61] , cannot be answered conclusively, particularly because CTNNB1 and APC were co-mutated in some of our LS tumours, possibly
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This observation is in agreement with Sekine et al. [62] , who found that RNF43 mutations, because of their association with MMR deficiency and thus with mutational burden in LS, commonly occur before adenoma formation in LS.
We hypothesize that tumour-suppressing inflammation in reference mucosa of G1 is induced by, among other factors, accumulation of frameshift peptides and possibly DNA lesions, owing to the larger mutational load in this group. Then, the transition from non-neoplastic, inflamed mucosa into tumour states is characterized by antagonistic alterations of inflammatory and proliferative transcription programmes, suggesting an immune escape mechanism. Strikingly, AIM2, encoding an innate immunity sensor that recognizes double-stranded DNA of microbial or host origin, is the only gene that is specifically and recurrently mutated in G1, being activated in reference mucosa and deactivated in tumours. Because AIM2 has been shown to activate several HLA class II genes [63] , its mutation might be an effective trigger for emerging tumour cells to escape the immunogenic microenvironment in G1 LS mucosa. AIM2 deficiency promotes uncontrolled proliferation of stem cells in the intestinal mucosa of mice, and increases the likelihood of sCRC development [64] . Deactivation of AIM2 is also associated with tumour burden in colitis-associated colon cancer (CAC) [65] . CAC is also characterized by mutations in KRAS and TP53, which are two important effectors of inflammatory pathways, whereby KRAS mutations appear as late events in CAC tumourigenesis, whereas loss of TP53 function is an early event; this order of events is not usually observed in 'normal' sCRC [59, 66, 67] . We found recurrent somatic mutations of these genes in G1 LS-CRC that were associated with deregulation of KRAS signalling and TP53 target expression, and decreased tumour-suppressing inflammation. A similar trend was found in KRAS-mutated MSS sCRC [44] , in contrast to MSI sCRCs, which upregulate inflammation upon tumourigenesis (supplementary material, Figure S10B ).
Immune editing in LS-CRC
Immune editing describes how anti-tumour immune surveillance of the host leads to the selection of tumour cells that evade immune cell recognition and destruction [9, 68] . Our results suggest that G1 tumour outgrowth is shaped by immune escape of emerging tumour cells in a highly immunogenic microenvironment in reference mucosa, mainly via two main mechanisms [46, 47] : (1) overexpression of ICGs in G1 reference mucosa, which inhibits local T-cell activity; and (2) loss of HLA presentation in G1 tumours, as indicated by deactivation of HLA gene expression. Both mechanisms potentially allow the elimination of oncogenic lesions to be circumvented. In consequence, immune editing suppresses the immune response in the resulting overt tumour in G1 as compared with reference mucosa. Immune editing by the loss of HLA type I and HLA type II genes has been demonstrated to occur in LS-CRC after mutations of the regulators B2M [9] and CIITA and RFX5 [46] , respectively. These regulators have been found to be coexpressed with the respective HLAs, but neither of these genes was found to be recurrently mutated in our G1 tumour samples, which suggests an alternative regulatory mechanism, possibly via deactivating AIM2 mutations, as discussed above. Strikingly, reference mucosa of G1 LS seems to share similarities with MSI sCRC, whereby high mutation rates activate the inflammatory response and ICG expression [13] . In contrast, low expression of ICG in G1 tumours shows analogy with MSS sCRC, which, in contrast to MSI sCRC, does not benefit from the administration of immune-checkpoint inhibitors [69] [70] [71] .
Limitations and outlook
The present study is limited by its small sample size. The need for higher-quality DNA and RNA and sequencing from fresh frozen material restricted us to analyses of 11 patients. We were able to collect only this limited number of paired tissue specimens with high enough quality for our analysis. Larger series of such reference mucosa and tumour samples in LS patients are clearly required to better resolve the molecular heterogeneity of LS in the colon, and to identify LS-specific mutational patterns, including more detailed MS characteristics and their stratification into subgroups. Our study shows that special attention should be directed to 'non-neoplastic' mucosa of LS constitutional mutation carriers to better understand the early phases of tumour development. This requires detailed genetic analyses in terms of somatic tissue-specific mutations and also of expressed neo-antigens. Our study has provided only the first indications of the importance of the immune response in the colon of LS patients, which clearly implies that more detailed analyses of the immune microenvironment are pertinent [72] . Finally, functional and clinical aspects must augment the molecular effects reported here, to address the possible consequences for tumour diagnosis and prevention in LS. Hence, our study contributes a working hypothesis to the field of carcinogenesis in LS mutation carriers that needs further investigation, because of its potential clinical implications. 17 Figure S1 . Mutation spectra of all LS-CRC cancer and adenoma samples Table S1 . Characteristics of LS-CRC patients included in this study Table S2 . Sample IDs used from TCGA Table S3 . Verification of selected mono-repeats using Sanger sequencing Table S4 . Number of somatic mutations (SNV) in LS-adenoma and -cancer samples Table S5 . Recurrently mutated genes in G1 LS-CRC Fig. S1 -Fig. S15 Supplementary Tables: Tab. S1 -Tab. S6 
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Microsatellite analysis using DNAseq
For MS-analysis all repeats with a total length of at least 5 bp within the human genome were annotated as reference. Then, the reads obtained in paired-end sequencing analysis of LS samples covering those repeats were identified. Only reads with a mapped mate read within a possible mapping window (four times the length of the mean insertion size that is calculated for every alignment independently) were taken into account to avoid false positive mappings.
Thereby, all reads were considered needed to cover the repeat itself, but also the corresponding 3'/5' adjacent region of at minimum 8 bp on both sides within a 100 bp window.
20 bp A/T mono-repeats in the reference genome, that were called instable in the LS CRCs, were used to calculate frequency distributions of the microsatellite length, also referred to as 'slippage profiles'. All reads related to repeats that were detectable with p-values <0.05 at least in one patient of the analyzed patient groups were used. Mean microsatellite lengths (MSL)
were determined by averaging the length of these repeats.
MS specificity analysis distinguishes G1 and G2 with high selectivity
In order to extract a subset of MS specific for G1 we applied the selection following criteria to all MS: i) have been measured in at least 8 patients ii) are instable in at least 3 G1 reference mucosa samples and/or in at least 3 G1 cancers iii) are stable in all G2 reference mucosa and cancers iv) are shorter than 21bp
where instability has been defined as a length difference of at least 1 bp between LS-patient and the reference genome (hg19).
This selection identified a subset of 77 MS (74 out of them are monorepeats) meeting the criteria. At least 61 MS out of the 77 MS selected were instable in any of the G1 patients (either in the reference mucosa, or in the tumor or in both, see Figure S 2A ), thus demonstrating a high homogeneity of G1 as classified by the MS.
In order to test the robustness of the groups, we performed a permutation test by assigning two patients of G2 to G1 and vice versa for all possible exchange-pairings (60 in total) and determined the number of MS that still fulfill criteria i) -iv). This strategy provides a distribution of the number of separating MS that would be expected if the group-labeling was random ( Figure S 2B ). This distribution is centered about 19 MS with an upper limit of 32 MS which is much smaller than the 77 MS separating G1 from G2.
Supplement 6
Notably, most MS instabilities were found in tumors and reference (57%) thus indicating emerging MS instabilities in reference mucosa.
HLA typing and neo-antigen prediction
HLA typing of each patient was performed using the OptiType algorithm [1] based on the DNA seq data of the LS reference tissue samples. For neoantigen prediction we processed the somatic mutations in LS CRC using the pVAC-Seq (v3.0.5) [2] pipeline. The binding affinities of all possible mutant amino acid 9-and 10-mers to the patient-specific HLA alleles were predicted using NetMHC (v3.4) [3] . Peptides with the binding affinity < 500nM were considered as potential neoantigens. A) The tree of expression portraits splits into four major branches which can be assigned to dominating functional signatures as indicated. Note that these four branches refer to regulatory states of the network shown in Figure S 7a . B) The tree of somatic SNV (for adenoma and cancer) and for differential mutations in reference mucosa shows that largest divergence is observed for G1 cancer and adenoma compared with reference tissue owing to the large number of somatic mutations which largely exceeds those in G2.
Figure S 7: SOM expression analysis:
A) The mutual co-expression of genes in the different tissue specimen was transformed into a network of gene clusters to visualize co-regulation of gene activity in the spot modules using the weighted topology overlap (wto) algorithm [4] . The network map visualizes mutual correlations (red edges) and anti-correlations (blue edges) between clusters of genes in different parts of the map. In a simplified view this network can be reduced to four main modules where the Mucosa and Stroma/Mesenchyme signatures on one hand and the Immune response and Proliferation signatures on the other hand switch in an antagonistic fashion, i.e. weak activity of the one implies strong expression of the other one and vice versa. We assigned potential constitutional mutation and the genes recurrently mutated in G1 cancer to the nodes of the network. The proliferative spot is depleted in mutated genes indicating that most somatic mutations are deactivating in the canonical cancer state. Notably, the suppression of the stromal signature associates with MLH1 constitutional and POLE and TGFBR2 damaging somatic mutations while the AIM2 mutation associates with the suppression of immune response in G1 cancer and adenoma. B) The variance map color codes the variability of the gene expression profiles of each metagene (pixel) of the SOM: Genes with highly variant expression arrange in the outer part of the map whereas invariant genes accumulate in the center. We used this information to filter mutated genes which show highly variant expression (marked by 'E' in Figure S 4 ). Their accumulation in and near the overexpression expression spots indicates concerted regulation. Member genes of the respective set are shown by dots where dots of larger sizes multiple occupancy (more than one gene per pixel). The genes accumulate in and near the spots as indicated by the red frames. The profiles estimate the expression of all genes of the set in each sample into one gene set enrichment score (GSZ). A) Literature sets related to sCRC and colonic inflammation: Spot A (and partly also B) accumulates genes differentially overexpressed in Ulcerative colitis (see [5, 6] ). The canonical CRC signature maps to spot D [7] . B) Sets of co-expressed genes derived from TCGA-data in this study: Activated genes in sCRC of the MSI and MSS subtypes of the TCGA data analyzed in this study accumulate in spot D whereas genes upregulated in healthy colonic tissue from TCGA show the mucosa signature (spot F). The MSI subtype combines signatures A -D. C) Gene sets related to expression programs in the healthy crypt: Sets of genes activated at the top and lower positions of colonic crypts reflecting either proliferative or mucosa signatures [8] . D) Gene set related to DNA repair mostly co-regulate with proliferation together with functions like 'translation' and 'ribosome' to account for the increased amount of DNA produced by the cell upon cell division (see also Figure S 8b ). APOBEC activity is a potential factor that accounts for differences of C>G conversions in the mutation spectra between G1 and G2 ( Figure S 1 ). E) Gene set related to immune response in sCRC: The 'coordinated immune response cluster' (CIRC) defines an immune signature in sCRC associated with tumor infiltrating lymphocytes [9] . This signature is activated in G1 reference mucosa and downregulated in G1 tumors (except Pat. 3). It coregulates with common immune checkpoint genes. F) Gene set related to DNA-methylation in sCRC: Genes hyper-and hypomethylated in sCRC taken from [10] accumulate in distinct spots. Note that hypermethylated genes in sCRC associate with the CIMP phenotype and give rise typically to under-expression of the affected genes [6] . We suggest that G1 cancer is shares similarities with CIMP-like hypermethylation. WNT-pathway activity in G1 reference mucosa and cancer. WNT-pathway topology shown in the part above was adapted from [11] . PSF estimates the transcriptional activity of genes in the pathway based on their expression values, their mutual interactions and assuming a 'signal flow' directed from 'input nodes' on the left to 'output nodes' on the right [12, 13] . In G1 LS-CRC cancer proliferative cellular programs become strongly activated due to deactivating mutations of ACVRA, TCF7L2 and especially TGFBR2 which associate with upregulation of MYC expression possibly because of the weakening of inhibitory effects along the pathway. Group data were obtained using mean expression values log-averaged over the samples of each of the groups. 
